United Therapeutics (UTHR) Misses Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $601.32 +0.87%
Revenue Growth %: -1.8%
Financial Fact:
Other, net: 1M
Today's EPS Names:
FUSE, INM, TRI, More
Revenue Growth %: -1.8%
Financial Fact:
Other, net: 1M
Today's EPS Names:
FUSE, INM, TRI, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $4.36, $0.08 worse than the analyst estimate of $4.44. Revenue for the quarter came in at $614.7 million versus the consensus estimate of $575.1 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- InnovAge (INNV) Tops Q1 EPS by 6c; Offers Guidance
- Quidel Corp (QDEL) Tops Q3 EPS by 11c; Offers Guidance
- Everus Construction Group, Inc. (ECG) Tops Q3 EPS by 101c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
